CompletedNot Applicable

Bridging Pediatric and Adult Biomarkers in Graft-Versus-Host Disease

United States415 participantsStarted 2014-01

Plain-language summary

This study is designed to collect longitudinal biological samples from patients after hematopoietic cell transplantation (HCT) cared for at multiple bone marrow transplant centers to validate biomarkers of both acute and chronic GVHD as well as for use in future unspecified research. The centers include Dana-Farber Cancer Institute and Boston's Children's Hospital, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Fred Hutchinson Cancer Research Center, Texas Children's Hospital, Children's National Medical Center, and Indiana University Simon Cancer Center.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: - All patients receiving an allogeneic hematopoietic stem cell transplant, cord blood transplant, bone marrow transplant, T cell depleted marrow, donor lymphocyte infusion (DLI), or donor cellular infusion (DCI) can be included. Exclusion Criteria: - patients not receiving an allogeneic hematopoietic stem cell transplant, cord blood transplant, bone marrow transplant, T cell depleted marrow, donor lymphocyte infusion (DLI), or donor cellular infusion (DCI) will be excluded.

What they're measuring

Number of Participants With Non Relapse Mortality (NRM) by Age and ST2 at 12 Months Post-HCT

Timeframe: 1 year

Trial details

NCT IDNCT02194439

SponsorIndiana University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2019-09-30

Results submitted2020-02-06

View on ClinicalTrials.gov More Graft-Versus-Host Disease trials